Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
11.17
-0.02 (-0.18%)
At close: Aug 8, 2025, 4:00 PM
11.16
-0.01 (-0.09%)
After-hours: Aug 8, 2025, 6:03 PM EDT
Dyne Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts that cover Dyne Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $38.31, which forecasts a 242.97% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $55.
Price Target: $38.31 (+242.97%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dyne Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 5 | 7 | 7 | 7 | 9 | 10 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 12 | 12 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $66 → $36 | Strong Buy | Maintains | $66 → $36 | +222.29% | Jul 31, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $25 → $23 | Buy | Maintains | $25 → $23 | +105.91% | Jul 29, 2025 |
| Raymond James | Raymond James | Buy Reiterates $37 → $31 | Buy | Reiterates | $37 → $31 | +177.53% | Jul 29, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $50 → $38 | Strong Buy | Maintains | $50 → $38 | +240.20% | Jul 29, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $10 → $9 | Hold | Maintains | $10 → $9 | -19.43% | Jul 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
839.58K
EPS This Year
-4.03
from -3.37
EPS Next Year
-3.96
from -4.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 9.6M | 208.7M | ||
| Avg | n/a | 839,583 | 99.4M | ||
| Low | n/a | n/a | 21.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 24,762.4% | ||
| Avg | - | - | 11,735.0% | ||
| Low | - | - | 2,467.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.53 | -3.21 | -2.27 | ||
| Avg | -4.03 | -3.96 | -3.38 | ||
| Low | -4.43 | -4.71 | -4.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.